Emcure to launch generic breast cancer medicine
Eribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Japan Health | Pharmaceuticals